Nuevolution A/S, a privately held drug discovery company announced that it has generated what it believes to be the world’s largest drug-like library comprising 100 million diverse compounds synthesised in a single test tube.

The company also identified novel drug lead candidates that inhibit the cancer target, integrin avb3 directly from this unprecedented library. Both library generation and lead candidate identification were performed in days using Nuevolution’s proprietary Chemetics drug discovery technology.

“The generation of this unique “ultra-large” compound library and the subsequent rapid identification of novel high potency drug candidates clearly demonstrate the tremendous power of Chemetics and represent a major milestone to establishing Nuevolution as a leading drug discovery Company”, commented Zahed Subhan PhD, chief executive officer of Nuevolution A/S.

Chemetics is poised to truly revolutionize the drug discovery process - it is the only technology available today that successfully combines ultra-large libraries of billions to trillions of drug-like small molecules with an accurate selection method that can efficiently handle such enormous numbers of compounds”.

“We are looking forward to building on these impressive achievements by consolidating our internal drug discovery pipeline as well as forging drug discovery alliances with leading pharmaceutical and biotech companies”, added Dr Subhan.

Nuevolution is a unique drug discovery company poised to revolutionize drug discovery and development by utilizing its proprietary Chemetics technology to rapidly generate tens to hundreds of potent, structurally diverse, small molecule clinical candidates to virtually any target in a matter of weeks.